 | • レポートコード：MRC2-11QY12570 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は黄斑変性症（AMD）のグローバル市場について調査・分析したレポートです。種類別（ルセンティス、アイレア、アバスチン、スクアラミン、コンセプト、ランパリザマブ、その他）市場規模、用途別（50〜60歳、60〜70歳、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別黄斑変性症（AMD）の競争状況、市場シェア ・世界の黄斑変性症（AMD）市場：種類別市場規模 2015年-2020年（ルセンティス、アイレア、アバスチン、スクアラミン、コンセプト、ランパリザマブ、その他） ・世界の黄斑変性症（AMD）市場：種類別市場規模予測 2021年-2026年（ルセンティス、アイレア、アバスチン、スクアラミン、コンセプト、ランパリザマブ、その他） ・世界の黄斑変性症（AMD）市場：用途別市場規模 2015年-2020年（50〜60歳、60〜70歳、その他） ・世界の黄斑変性症（AMD）市場：用途別市場規模予測 2021年-2026年（50〜60歳、60〜70歳、その他） ・北米の黄斑変性症（AMD）市場分析：米国、カナダ ・ヨーロッパの黄斑変性症（AMD）市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの黄斑変性症（AMD）市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の黄斑変性症（AMD）市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの黄斑変性症（AMD）市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Novartis、Bayer Healthcare、Roche、Neurotech Pharmaceuticals、Regeneron Pharmaceuticals、Allergan ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above.
The North American region is the most lucrative market, owing to large number of elderly population in the U.S. However, European and Asia-Pacific regions are considered as the most promising markets in the upcoming period.
Market Analysis and Insights: Global Macular Degeneration Drugs Market
The global Macular Degeneration Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Macular Degeneration Drugs Scope and Market Size
Macular Degeneration Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Macular Degeneration Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan
…
Market segment by Type, the product can be split into
Lucentis
Eylea
Avastin
Squalamine
Conercept
Lampalizamab
Other
Market segment by Application, split into
50-60 Years Old
60-70 Years Old
Other
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Macular Degeneration Drugs Revenue
1.4 Market by Type
1.4.1 Global Macular Degeneration Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Lucentis
1.4.3 Eylea
1.4.4 Avastin
1.4.5 Squalamine
1.4.6 Conercept
1.4.7 Lampalizamab
1.4.8 Other
1.5 Market by Application
1.5.1 Global Macular Degeneration Drugs Market Share by Application: 2020 VS 2026
1.5.2 50-60 Years Old
1.5.3 60-70 Years Old
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Macular Degeneration Drugs Market Perspective (2015-2026)
2.2 Global Macular Degeneration Drugs Growth Trends by Regions
2.2.1 Macular Degeneration Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Macular Degeneration Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Macular Degeneration Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Macular Degeneration Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Macular Degeneration Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Macular Degeneration Drugs Players by Market Size
3.1.1 Global Top Macular Degeneration Drugs Players by Revenue (2015-2020)
3.1.2 Global Macular Degeneration Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Macular Degeneration Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Macular Degeneration Drugs Market Concentration Ratio
3.2.1 Global Macular Degeneration Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Macular Degeneration Drugs Revenue in 2019
3.3 Macular Degeneration Drugs Key Players Head office and Area Served
3.4 Key Players Macular Degeneration Drugs Product Solution and Service
3.5 Date of Enter into Macular Degeneration Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Macular Degeneration Drugs Historic Market Size by Type (2015-2020)
4.2 Global Macular Degeneration Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Macular Degeneration Drugs Market Size by Application (2015-2020)
5.2 Global Macular Degeneration Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Macular Degeneration Drugs Market Size (2015-2020)
6.2 Macular Degeneration Drugs Key Players in North America (2019-2020)
6.3 North America Macular Degeneration Drugs Market Size by Type (2015-2020)
6.4 North America Macular Degeneration Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Macular Degeneration Drugs Market Size (2015-2020)
7.2 Macular Degeneration Drugs Key Players in Europe (2019-2020)
7.3 Europe Macular Degeneration Drugs Market Size by Type (2015-2020)
7.4 Europe Macular Degeneration Drugs Market Size by Application (2015-2020)
8 China
8.1 China Macular Degeneration Drugs Market Size (2015-2020)
8.2 Macular Degeneration Drugs Key Players in China (2019-2020)
8.3 China Macular Degeneration Drugs Market Size by Type (2015-2020)
8.4 China Macular Degeneration Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Macular Degeneration Drugs Market Size (2015-2020)
9.2 Macular Degeneration Drugs Key Players in Japan (2019-2020)
9.3 Japan Macular Degeneration Drugs Market Size by Type (2015-2020)
9.4 Japan Macular Degeneration Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Macular Degeneration Drugs Market Size (2015-2020)
10.2 Macular Degeneration Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Macular Degeneration Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Macular Degeneration Drugs Market Size by Application (2015-2020)
11 India
11.1 India Macular Degeneration Drugs Market Size (2015-2020)
11.2 Macular Degeneration Drugs Key Players in India (2019-2020)
11.3 India Macular Degeneration Drugs Market Size by Type (2015-2020)
11.4 India Macular Degeneration Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Macular Degeneration Drugs Market Size (2015-2020)
12.2 Macular Degeneration Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Macular Degeneration Drugs Market Size by Type (2015-2020)
12.4 Central & South America Macular Degeneration Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Novartis
13.1.1 Novartis Company Details
13.1.2 Novartis Business Overview
13.1.3 Novartis Macular Degeneration Drugs Introduction
13.1.4 Novartis Revenue in Macular Degeneration Drugs Business (2015-2020))
13.1.5 Novartis Recent Development
13.2 Bayer Healthcare
13.2.1 Bayer Healthcare Company Details
13.2.2 Bayer Healthcare Business Overview
13.2.3 Bayer Healthcare Macular Degeneration Drugs Introduction
13.2.4 Bayer Healthcare Revenue in Macular Degeneration Drugs Business (2015-2020)
13.2.5 Bayer Healthcare Recent Development
13.3 Roche
13.3.1 Roche Company Details
13.3.2 Roche Business Overview
13.3.3 Roche Macular Degeneration Drugs Introduction
13.3.4 Roche Revenue in Macular Degeneration Drugs Business (2015-2020)
13.3.5 Roche Recent Development
13.4 Neurotech Pharmaceuticals
13.4.1 Neurotech Pharmaceuticals Company Details
13.4.2 Neurotech Pharmaceuticals Business Overview
13.4.3 Neurotech Pharmaceuticals Macular Degeneration Drugs Introduction
13.4.4 Neurotech Pharmaceuticals Revenue in Macular Degeneration Drugs Business (2015-2020)
13.4.5 Neurotech Pharmaceuticals Recent Development
13.5 Regeneron Pharmaceuticals
13.5.1 Regeneron Pharmaceuticals Company Details
13.5.2 Regeneron Pharmaceuticals Business Overview
13.5.3 Regeneron Pharmaceuticals Macular Degeneration Drugs Introduction
13.5.4 Regeneron Pharmaceuticals Revenue in Macular Degeneration Drugs Business (2015-2020)
13.5.5 Regeneron Pharmaceuticals Recent Development
13.6 Allergan
13.6.1 Allergan Company Details
13.6.2 Allergan Business Overview
13.6.3 Allergan Macular Degeneration Drugs Introduction
13.6.4 Allergan Revenue in Macular Degeneration Drugs Business (2015-2020)
13.6.5 Allergan Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Macular Degeneration Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Macular Degeneration Drugs Revenue
Table 3. Ranking of Global Top Macular Degeneration Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Macular Degeneration Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Lucentis
Table 6. Key Players of Eylea
Table 7. Key Players of Avastin
Table 8. Key Players of Squalamine
Table 9. Key Players of Conercept
Table 10. Key Players of Lampalizamab
Table 11. Key Players of Other
Table 12. Global Macular Degeneration Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Macular Degeneration Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Macular Degeneration Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Macular Degeneration Drugs Market Share by Regions (2015-2020)
Table 16. Global Macular Degeneration Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Macular Degeneration Drugs Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Macular Degeneration Drugs Market Growth Strategy
Table 22. Main Points Interviewed from Key Macular Degeneration Drugs Players
Table 23. Global Macular Degeneration Drugs Revenue by Players (2015-2020) (Million US$)
Table 24. Global Macular Degeneration Drugs Market Share by Players (2015-2020)
Table 25. Global Top Macular Degeneration Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Degeneration Drugs as of 2019)
Table 26. Global Macular Degeneration Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Macular Degeneration Drugs Product Solution and Service
Table 29. Date of Enter into Macular Degeneration Drugs Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Macular Degeneration Drugs Market Size by Type (2015-2020) (Million US$)
Table 32. Global Macular Degeneration Drugs Market Size Share by Type (2015-2020)
Table 33. Global Macular Degeneration Drugs Revenue Market Share by Type (2021-2026)
Table 34. Global Macular Degeneration Drugs Market Size Share by Application (2015-2020)
Table 35. Global Macular Degeneration Drugs Market Size by Application (2015-2020) (Million US$)
Table 36. Global Macular Degeneration Drugs Market Size Share by Application (2021-2026)
Table 37. North America Key Players Macular Degeneration Drugs Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Macular Degeneration Drugs Market Share (2019-2020)
Table 39. North America Macular Degeneration Drugs Market Size by Type (2015-2020) (Million US$)
Table 40. North America Macular Degeneration Drugs Market Share by Type (2015-2020)
Table 41. North America Macular Degeneration Drugs Market Size by Application (2015-2020) (Million US$)
Table 42. North America Macular Degeneration Drugs Market Share by Application (2015-2020)
Table 43. Europe Key Players Macular Degeneration Drugs Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Macular Degeneration Drugs Market Share (2019-2020)
Table 45. Europe Macular Degeneration Drugs Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Macular Degeneration Drugs Market Share by Type (2015-2020)
Table 47. Europe Macular Degeneration Drugs Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Macular Degeneration Drugs Market Share by Application (2015-2020)
Table 49. China Key Players Macular Degeneration Drugs Revenue (2019-2020) (Million US$)
Table 50. China Key Players Macular Degeneration Drugs Market Share (2019-2020)
Table 51. China Macular Degeneration Drugs Market Size by Type (2015-2020) (Million US$)
Table 52. China Macular Degeneration Drugs Market Share by Type (2015-2020)
Table 53. China Macular Degeneration Drugs Market Size by Application (2015-2020) (Million US$)
Table 54. China Macular Degeneration Drugs Market Share by Application (2015-2020)
Table 55. Japan Key Players Macular Degeneration Drugs Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Macular Degeneration Drugs Market Share (2019-2020)
Table 57. Japan Macular Degeneration Drugs Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Macular Degeneration Drugs Market Share by Type (2015-2020)
Table 59. Japan Macular Degeneration Drugs Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Macular Degeneration Drugs Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Macular Degeneration Drugs Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Macular Degeneration Drugs Market Share (2019-2020)
Table 63. Southeast Asia Macular Degeneration Drugs Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Macular Degeneration Drugs Market Share by Type (2015-2020)
Table 65. Southeast Asia Macular Degeneration Drugs Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Macular Degeneration Drugs Market Share by Application (2015-2020)
Table 67. India Key Players Macular Degeneration Drugs Revenue (2019-2020) (Million US$)
Table 68. India Key Players Macular Degeneration Drugs Market Share (2019-2020)
Table 69. India Macular Degeneration Drugs Market Size by Type (2015-2020) (Million US$)
Table 70. India Macular Degeneration Drugs Market Share by Type (2015-2020)
Table 71. India Macular Degeneration Drugs Market Size by Application (2015-2020) (Million US$)
Table 72. India Macular Degeneration Drugs Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Macular Degeneration Drugs Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Macular Degeneration Drugs Market Share (2019-2020)
Table 75. Central & South America Macular Degeneration Drugs Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Macular Degeneration Drugs Market Share by Type (2015-2020)
Table 77. Central & South America Macular Degeneration Drugs Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Macular Degeneration Drugs Market Share by Application (2015-2020)
Table 79. Novartis Company Details
Table 80. Novartis Business Overview
Table 81. Novartis Product
Table 82. Novartis Revenue in Macular Degeneration Drugs Business (2015-2020) (Million US$)
Table 83. Novartis Recent Development
Table 84. Bayer Healthcare Company Details
Table 85. Bayer Healthcare Business Overview
Table 86. Bayer Healthcare Product
Table 87. Bayer Healthcare Revenue in Macular Degeneration Drugs Business (2015-2020) (Million US$)
Table 88. Bayer Healthcare Recent Development
Table 89. Roche Company Details
Table 90. Roche Business Overview
Table 91. Roche Product
Table 92. Roche Revenue in Macular Degeneration Drugs Business (2015-2020) (Million US$)
Table 93. Roche Recent Development
Table 94. Neurotech Pharmaceuticals Company Details
Table 95. Neurotech Pharmaceuticals Business Overview
Table 96. Neurotech Pharmaceuticals Product
Table 97. Neurotech Pharmaceuticals Revenue in Macular Degeneration Drugs Business (2015-2020) (Million US$)
Table 98. Neurotech Pharmaceuticals Recent Development
Table 99. Regeneron Pharmaceuticals Company Details
Table 100. Regeneron Pharmaceuticals Business Overview
Table 101. Regeneron Pharmaceuticals Product
Table 102. Regeneron Pharmaceuticals Revenue in Macular Degeneration Drugs Business (2015-2020) (Million US$)
Table 103. Regeneron Pharmaceuticals Recent Development
Table 104. Allergan Company Details
Table 105. Allergan Business Overview
Table 106. Allergan Product
Table 107. Allergan Revenue in Macular Degeneration Drugs Business (2015-2020) (Million US$)
Table 108. Allergan Recent Development
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Macular Degeneration Drugs Market Share by Type: 2020 VS 2026
Figure 2. Lucentis Features
Figure 3. Eylea Features
Figure 4. Avastin Features
Figure 5. Squalamine Features
Figure 6. Conercept Features
Figure 7. Lampalizamab Features
Figure 8. Other Features
Figure 9. Global Macular Degeneration Drugs Market Share by Application: 2020 VS 2026
Figure 10. 50-60 Years Old Case Studies
Figure 11. 60-70 Years Old Case Studies
Figure 12. Other Case Studies
Figure 13. Macular Degeneration Drugs Report Years Considered
Figure 14. Global Macular Degeneration Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Macular Degeneration Drugs Market Share by Regions: 2020 VS 2026
Figure 16. Global Macular Degeneration Drugs Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Macular Degeneration Drugs Market Share by Players in 2019
Figure 19. Global Top Macular Degeneration Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Macular Degeneration Drugs as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Macular Degeneration Drugs Revenue in 2019
Figure 21. North America Macular Degeneration Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Macular Degeneration Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Macular Degeneration Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Macular Degeneration Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Macular Degeneration Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Macular Degeneration Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Macular Degeneration Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bottom-up and Top-down Approaches for This Report
Figure 29. Data Triangulation
Figure 30. Key Executives Interviewed
黄斑変性症（AMD）・糖尿病性網膜症（DR）治療薬の世界市場（～2026年） Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is usually an age-related disorder, which affects adults with the age 50 and above. Diabetic retinopathy is an ophthalmic disorder, in which b…- 加齢黄斑変性症（AMD）遺伝子治療の世界市場（～2026年） Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is dire…
- 若年性黄斑変性症治療の世界市場（～2026年） Market Analysis and Insights: Global Juvenile Macular Degeneration Treatment Market The global Juvenile Macular Degeneration Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Juvenile Macular Degeneration Treat…
- 加齢性黄斑変性症の世界市場（～2026年） Market Analysis and Insights: Global Age-related Macular Degeneration Market The global Age-related Macular Degeneration market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Age-related Macular Degeneration Scope and Market…
- 加齢性黄斑変性症（AMD）の世界市場（～2026年） Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss,…